Following the science from prostate cancer’s “on switch” to the Sjöberg Prize

Nearly 2 decades after a groundbreaking discovery, Arul Chinnaiyan wins a prestigious cancer research award.

2:45 PM

Author | Nicole Fawcett

Doctors talking in office wearing white lab coats and masks.
Arul Chinnaiyan, M.D., Ph.D., in his lab. Credit: Bryan McCullough

In 2005, Arul Chinnaiyan, M.D., Ph.D., and his lab found what they realized was the "on switch" for prostate cancer. A gene regulated by androgens called TMPRSS2 fuses with a transcription factor called ERG to trigger the development of prostate cancer.

This gene fusion was the first ever identified in solid tumors. In the nearly two decades since, the Chinnaiyan lab has refined its discovery, understanding how the hormone androgen regulates this gene fusion and developing a urine-based screening test to better detect prostate cancer.

MORE FROM THE LAB: Subscribe to our weekly newsletter

For this work, Chinnaiyan, S.P. Hicks Professor of Pathology and Urology at Michigan Medicine, was named the winner of the 2022 Sjöberg Prize, awarded by the Royal Swedish Academy of Sciences, which also awards Nobel Prizes.

This is the sixth time the Sjöberg Prize has been presented. It was established by businessman Bengt Sjöberg to promote scientific research primarily focused on cancer, health and the environment. The Royal Swedish Academy selects the laureates and the Sjöberg Foundation provides the $1 million prize funding.

"One of the things that made the TMPRSS2::ERG gene fusion unique and exciting is that it is found only in prostate cancer, not in normal prostate tissue," said Chinnaiyan, director of the Michigan Center for Translational Pathology and a member of the University of Michigan Health Rogel Cancer Center. 

This allowed the lab to significantly improve on the traditional prostate specific antigen, or PSA, test to detect prostate cancer. They combined the gene fusion, PSA and one other prostate cancer marker into a urine test called MyProstate Score, or MPS. Studies have shown this test is more accurate than a standard PSA test for predicting cancer as well as predicting aggressive prostate cancer. The test is commercially available.

In addition, the Chinnaiyan lab has used the technology behind this discovery to uncover gene fusions in other common cancers. They continue to investigate how these fusions can be targeted for treatment.

Here, Chinnaiyan reflects on his discovery and shares what it means to win the Sjöberg Prize.

What did you think when you first heard you won the Sjöberg Prize?

Chinnaiyan: To receive an email from the Royal Swedish Academy of Sciences was a pleasant surprise, especially considering the isolation during these pandemic times. I was even more thrilled to hear I was selected for the 2022 Sjöberg Prize. It is a great honor to be selected for this award and to follow in the footsteps of the luminaries who have received this award in the past.  

What has been the impact of the gene fusion discovery?

Chinnaiyan: The discovery of recurrent gene fusions in prostate cancer was certainly a stunning finding back in 2005. Before that time, it was thought that gene fusions and translocations were major drivers of hematological cancers and rare soft tissue tumors. But we had found these gene fusions in high prevalence in a common solid tumor, that being prostate cancer. 

The TMPRSS2-ETS fusions that we identified ended up being exquisitely specific biomarkers of prostate cancer that can be detected in prostate needle biopsies and non-invasively in the urine of men with prostate cancer.

After our discovery, a number of recurrent gene fusions were identified in subsets of other common solid tumors, including lung cancer, breast cancer and melanoma, among others. The finding of recurrent gene fusions in prostate cancer also opened up the use of transcriptome or RNA-sequencing in precision oncology efforts. 

How will you use the award money?

Chinnaiyan: As this award recognizes our discovery of recurrent gene fusions in prostate cancer, I plan to use this support to fund our efforts to directly and indirectly therapeutically target these and other cancer-causing transcription factors. As transcription factors have been challenging to develop drugs against, we plan to approach this from a variety of angles. 

Again, I'm grateful to theRoyal Swedish Academy of Sciences and the Sjöberg Prize Committee for recognizing our work.

Like Podcasts? Add the Michigan Medicine News Break on iTunes or anywhere you listen to podcasts.


More Articles About: Lab Report Prostate Cancer Cancer Research Cancer: Cancer Types
Health Lab word mark overlaying blue cells
Health Lab

This article is from the Health Lab digital publication.

Media Contact Public Relations

Department of Communication at Michigan Medicine

MichMedmedia@med.umich.edu

734-764-2220

Newsletter

Get a weekly digest of medical research and innovation, straight to your inbox.

Subscribe
Featured News & Stories human silhouette groin zoom prostate
Health Lab
Study suggests commonly used prostate cancer treatment rewires engine of prostate tumors
Biopsies from the same patients before and after treatment reveal how a specific drug reprograms prostate tumors.
cells under microscope #D render particles
Health Lab
Study demonstrates a novel approach to target enhancer-addicted cancers
A chromatin degrader stops transcription factors from driving cancer, which may serve as a potential treatment approach for over 90% of prostate cancers.
pink purple spongy tissue under microscope view
Health Lab
BET inhibitors show promise in overcoming lineage plasticity, a newly recognized form of resistance to prostate cancer drugs
Some prostate tumors transition from being glandular to more nerve-like in response to drugs that block the androgen receptor; a new preclinical study examines the underlying mechanisms and uncovers a promising countermeasure.
MRI scanning procedure
Health Lab
Clinical Trial Offers Clues About Why Some Metastatic Prostate Cancers Don’t Respond to Anti-Androgen Therapy
Transcriptional profiling identifies a gene program active in metastatic prostate cancers that failed to respond to enzalutamide treatment.
Doctors looking at sample
Health Lab
Newly Defined Cancer Driver is Fast, Furious and Loud
Researchers characterize three ways in which the gene FOXA1 mutates to trigger prostate cancer.
people
Health Lab
Study Explores Why Prostate Cancer Mortality is Higher in Black Men
The largest study of its kind finds societal factors and access to quality care, rather than genetics, underlies higher prostate cancer mortality rates for black men.